Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.
Inger Johanne Zwicky EideHarald GrutÅslaug HellandSimon EkmanJens Benn SørensenKarin Holmskov HansenBjørn Henning GrønbergSaulius CicenasJussi Pekka KoivunenAnders MellemgaardOdd Terje BrustugunPublished in: Acta oncologica (Stockholm, Sweden) (2021)
This subgroup analysis confirms CNS efficacy of osimertinib in patients with the T790M resistance mutation, while other treatment options should be considered for EGFR-TKI relapsed T790M-negative patients with brain metastases.
Keyphrases
- small cell lung cancer
- brain metastases
- phase ii study
- epidermal growth factor receptor
- acute lymphoblastic leukemia
- acute myeloid leukemia
- multiple myeloma
- tyrosine kinase
- advanced non small cell lung cancer
- hodgkin lymphoma
- diffuse large b cell lymphoma
- open label
- locally advanced
- single cell
- cell therapy
- blood brain barrier
- squamous cell carcinoma
- phase iii
- radiation therapy
- mesenchymal stem cells